PDCD1 and hepatocellular carcinoma: Therefore, we infer that MDZ enhances the efficacy of PD-1/PD-L1 blockade therapy by downregulating PD-L1 expression in HCC cells by inhibiting the NF-κB/p-NF-κB pathway.